Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Cross Above 50 Day Moving Average – Here’s Why

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.67 and traded as high as $1.05. Eagle Pharmaceuticals shares last traded at $0.80, with a volume of 19,398 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Eagle Pharmaceuticals in a research report on Friday. They issued a “hold” rating on the stock.

Eagle Pharmaceuticals Stock Up 22.5 %

The company has a 50-day simple moving average of $0.68 and a 200 day simple moving average of $2.40.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new position in Eagle Pharmaceuticals during the 2nd quarter valued at about $971,000. RBF Capital LLC increased its holdings in shares of Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $453,000. DGS Capital Management LLC boosted its holdings in shares of Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after acquiring an additional 22,239 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Eagle Pharmaceuticals during the 3rd quarter worth approximately $96,000. 85.36% of the stock is currently owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.